Month: May 2024

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

Written by Customer Service on May 29, 2024. Posted in Earnings Releases And Operating Results.

TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca. Key Business Highlights On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities,...

Danforth Advisors Acquires BW Health Group; Adds Commercial Readiness and Launch to Range of Integrated Services for Life Science Companies

Written by Customer Service on May 29, 2024. Posted in Mergers And Acquisitions.

WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) — Danforth Advisors, LLC, today announced the acquisition of BW Health Group, a leading provider of commercial readiness and product launch services for small and mid-sized life science companies. The addition of BW gives Danforth an unrivaled capability to serve the strategic and operational needs of life science companies to run their business, develop products and successfully bring them to market. These services include advisory and execution in finance and accounting, strategic communications, human resources, enterprise risk management, clinical operations, regulatory affairs and now commercialization. “Since inception, we have strategically curated the talent, skill sets, services and connections required to be the flexible infrastructure partner to life science companies. We...

Tevogen Bio Reports First Quarter 2024 Financial Results

Written by Customer Service on May 29, 2024. Posted in Earnings Releases And Operating Results.

Confirms liability elimination of $94.9 million and discloses $11.3 million of net income Reports net cash used for operating activities was $2.1 million Reiterates commitment to both patients and shareholdersWARREN, N.J., May 29, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ended March 31, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. As of March 31, 2024, Tevogen has eliminated $94.9 million in balance sheet liabilities as compared to December 31, 2023, by converting convertible promissory notes into shares of...

Gentex Announces Second Quarter 2024 Cash Dividend

Written by Customer Service on May 29, 2024. Posted in Dividend Reports And Estimates.

ZEELAND, Mich., May 29, 2024 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, and fire protection technologies, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.12 (12 cents) per share that will be payable July 17, 2024, to shareholders of record of the common stock at the close of business on July 5, 2024. About the CompanyFounded in 1974, Gentex Corporation (The NASDAQ Global Select Market: GNTX) is a supplier of automatic-dimming rearview mirrors and electronics to the automotive industry, dimmable aircraft windows for aviation markets, and fire protection products to the fire protection market. Visit the Company’s websites at www.gentex.com, fulldisplaymirror.com, and ir.gentex.com/. Contact...

Reed’s Unveils New Virgil’s 12oz Can Format in Sprouts Farmers Market

Written by Customer Service on May 29, 2024. Posted in Public Companies.

NORWALK, Conn., May 29, 2024 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the launch of Virgil’s full sugar handcrafted sodas in a new, convenient 12oz can format for five classic flavors in Sprouts Farmers Market nationwide. “We’re thrilled to unveil Virgil’s handcrafted sodas in a convenient, easy-to-carry 12oz can format, catering to consumer preferences and the rising demand for on-the-go beverages,” said Norman E. Snyder, Jr., CEO of Reed’s. “Our classic flavors, previously available only in bottles, are now more accessible than ever, allowing our customers to enjoy Virgil’s premium sodas wherever they go. We’re initially launching the new can format in Sprout’s nationwide and look forward...

KULR Experiences Fast-Growing Demand for Next-Gen EV Battery Safety and Testing Solutions with Order from Top Japanese Automaker

Written by Customer Service on May 29, 2024. Posted in Public Companies.

Battery Testing and Analysis Services Unit to Generate $8 Million to $10 Million Revenue Annually Starting in 2025 SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today announced it has secured a contract from a top Japanese multinational automaker (“Automaker”) for testing and analysis of high-energy battery cells intended for their next-generation electric vehicles. The Company will utilize its KULR ONE Design Solutions (K1-DS) platform to expedite design readiness for the Automaker’s future electric vehicle buildout. KULR’s extensive spaceflight expertise and proprietary KULR ONE Design Solutions are integrated into its rigorous testing protocols, forming what KULR believes to be the world’s most comprehensive...

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

Written by Customer Service on May 29, 2024. Posted in Public Companies.

ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex® SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Dr. Andrew Yates presented new pre-clinical data on ART12.11 at the CT-CANN24 conference which is being held May 29-30, 2024 at the Hilton London Canary Wharf in London, UK. The presentation, titled “An Aqueous Suspension of a Novel Cannabidiol: Tetramethylpyrazine Co-crystal, demonstrates a pharmacokinetic profile comparable with Epidiolex® in Rats,” highlights the Company’s patented cocrystal of CBD and TMP (tetramethylpyrazine), ART12.11, in an unoptimized formulation,...

Rivian Founder and CEO RJ Scaringe to Participate in Bernstein’s 40th Annual Strategic Decisions Conference

Written by Customer Service on May 29, 2024. Posted in Public Companies.

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) — Rivian (NASDAQ: RIVN), has today announced that at 8.00am EDT on May 30, 2024, its Founder and CEO RJ Scaringe will participate in a fireside chat at Bernstein’s 40th Annual Strategic Decisions Conference. A live webcast of the fireside chat will be available here. Investor Contact:ir@rivian.com Media Contact:Harry Porter: media@rivian.com About Rivian:Rivian (NASDAQ: RIVN) is an American automotive manufacturer that develops and builds category-defining electric vehicles and accessories. The company creates innovative and technologically advanced products that are designed to excel at work and play with the goal of accelerating the global transition to zero-emission transportation and energy. Rivian vehicles are built in the United States and are sold directly to consumer and commercial...

Nordea Bank Abp is planning to make fee adjustments in order to address its increased costs of hedging

Written by Customer Service on May 29, 2024. Posted in Public Companies.

Due to increased costs Nordea Abp will adjust the Base Rate Margin (which in previous base prospectuses also has been referred to as “räntebasmarginal ”) for Nordea branded bull and bear certificates. The relevant Base Rates may either be decreased or increased on isin level, but the adjustments will in general consist of fee increases. The fee adjustments will be effective from the 14th of June 2024. All affected instruments will be traded just as any other trading day both until and after that date. Affected instruments can be found in the pdf.AttachmentAffected instruments

Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

Written by Customer Service on May 29, 2024. Posted in Public Companies.

ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the forefront as the first in the Northeast United States to offer the Genesis System. Genesis is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals